We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




PET Imaging Used to Monitor Beta Cell Status in Type 1 Diabetes

By MedImaging International staff writers
Posted on 02 Jul 2014
Print article
Type 1 diabetes (T1D) is a disorder that involves the progressive loss of insulin-producing beta cells, but calculating that loss has continued to mystify researchers, at least until the present. Swedish researchers are now using a radiotracer or marker and positron emission tomography (PET) scanning as a noninvasive technique to track changes in how many active beta cells are contained in an individual.

Dr. Olle Korsgren and his colleagues at the University of Uppsala (Sweden) used the imaging technology in a clinical study of 10 individuals with T1D and nine without the disease to compare the amount of beta cells in each group. They discovered that the amount or volume of active beta cells was substantially lower in the group with T1D compared to those without T1D, and the reduction was close to what researchers predicted given a loss of the majority of beta cells in the pancreas in T1D. In another study of people with type 2 diabetes, the researchers were able to use the technique to identify a progressive loss of the amount of beta cells in one person imaged repeatedly over a two-year period.

The PET imaging technique is based on recently discovered biologic processes that occur in the beta cell. One specific process in the beta cell causes the cells to take up a typically used imaging radiotracer given at the start of the procedure. The amount of the tracer that is deposited in the pancreas mostly depends on how many beta cells are alive and active. The PET scan can then detect the amount of radiotracer in the pancreas as an approximate measure of the overall amount or volume of beta cells present. The procedure takes only a few hours to complete.

This imaging technique will most likely have no role in diagnosing T1D because of the large variability of the number of beta cells among people with T1D and even among those without T1D. However, it could become a major approach for tracking the loss of beta cells in a person at risk of T1D and as a faster and more precise way to evaluate the benefit of novel beta cell survival and regeneration therapies. More human validation studies of this technique are needed before it can be used routinely.

Related Links:

University of Uppsala


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound Needle Guide
Ultra-Pro II
New
PACS Workstation
CHILI Web Viewer
New
Ultrasound Software
UltraExtend NX

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.